AstraZeneca to Buy ZS Pharma for $2.7 Billion in Cash Deal
AstraZeneca to Buy ZS Pharma for $2.7 Billion in Cash Deal
AstraZeneca Plc agreed to buy ZS Pharma for $2.7 billion in cash, scooping up a potential blockbuster medicine for a deadly blood condition that had also attracted Swiss drugmaker Actelion Ltd.
Bloomberg
Bloomberg
AstraZeneca to Buy ZS Pharma for $2.7 Billion in Cash Deal
AstraZeneca to Buy ZS Pharma for $2.7 Billion in Cash Deal
AstraZeneca Plc, the U.K.’s second-largest drugmaker, agreed to buy ZS Pharma of California for $2.7 billion in cash to gain a potential blockbuster medicine for a deadly condition.
Bloomberg
Bloomberg
US jobs data smash forecasts and send dollar soaring – as it happened
US jobs data smash forecasts and send dollar soaring – as it happened
The US economy created 271,000 new jobs in October, almost 100,000 more than expected. Dollar rallies as December rate hike looks like a done deal
The Guardian - UK
The Guardian - UK
FTSE falls ahead of Bank rate decision but AstraZeneca and RSA rise
Investors nervous about interest rates but positive updates give some support
The Guardian - UK
The Guardian - UK
From analysis to the latest developments in health, read the most diverse news in one place.
Already a member? Sign in here
AstraZeneca Bets Cancer Picks Up Diabetes Slack in New Plan
AstraZeneca Plc projected a slowdown in U.S. sales of diabetes treatments, echoing comments by competitors and putting the onus on its cancer drugs to help meet its long- term sales target.
Bloomberg
Bloomberg
Allergan Third-Quarter Profit Tops Estimates as Sales Climb
Allergan Plc, Pfizer Inc.’s target in a deal that could be the largest health-care acquisition of all time, reported third-quarter earnings that topped analysts’ estimates as the company’s recent takeovers added to revenue.
Bloomberg
Bloomberg